Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now
0.0000
0.0000
(0.00%)
At close: January 14 at 3:39:38 PM EST
Key Executives
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Kevin C. Tang | Chairman & CEO | 1 | -- | 1967 |
| Mr. Michael S. Hearne CPA | CFO & Principal Accounting Officer | 251.23k | -- | 1963 |
| Mr. Ryan Cole | Senior Vice President of Operations | -- | -- | -- |
| Dr. Steven S. Pfeiffer Ph.D. | Senior Vice President of Technical Operations | -- | -- | 1976 |
Odonate, Inc.
- Sector:
- Financial Services
- Industry: Shell Companies
- Full Time Employees:
- 137
Description
Odonate, Inc., a pharmaceutical company, develops therapeutics for the treatment of cancer. It is developing tesetaxel, an orally administered chemotherapy agent, which is in Phase III clinical study for patients with metastatic breast cancer. The company was formerly known as Odonate Therapeutics, Inc. and changed its name to Odonate, Inc. in March 2023. The company was founded in 2013 and is based in New York, New York.
Corporate Governance
Odonate, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Upcoming Events
Upcoming Events Information Not Available
Recent Events
February 7, 2022 at 12:00 AM UTC
15-12B: Notice of termination of registration of a class of securities under Section 12(b)